Personalized therapy and pharmacogenomics: Future perspective

Pharmacogenomics

Volumn 10, Issue 6, 2009, Pages 927-930

  Siest, Gerard ^a   Marteau, Jean Brice ^a   Visvikis Siest, Sophie ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSIGLITAZONE; WARFARIN;

BIOMEDICINE; DNA METHYLATION; DRUG DESIGN; DRUG INDUSTRY; DRUG TARGETING; EDITORIAL; EDUCATION PROGRAM; GENE TECHNOLOGY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MEDICAL EDUCATION; PERSONALIZED MEDICINE; PHARMACOGENOMICS; SYSTEMS BIOLOGY;

DRUG DISCOVERY; FORECASTING; HUMANS; PHARMACOGENETICS;

EID: 69049110101     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.45     Document Type: Editorial

References (28)

1. Siest G, Bastien B, Benachour H et al.: From human genetic variations to prediction of risks and responses to drugs and the environment. Per. Med. 4, 95-104 (2007).
2. Siest G, Benachour H, Lambert D et al.: Functional genomics towards personalized healthcare. Per. Med. 6,19-32 (2009).
3. Gurwitz D, Lunshof JE, Dedoussis G et al.: Pharmacogenomics education: international society of pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J. 5, 221-225 (2005).
4. Koster ES, Maitland-van der Zee AH, Rodin AS, Raaijmakers JAM: Systems biology in pharmacogenomic research: the way to personalized prescribing? Pharmacogenomics 10(6), 971-981 (2009).
5. Winkelmann BR: The cardiovascular genomics revolution - where is the clinical benefit? Clin. Chem. Lab. Med. 46, A107 (2008).
6. Becquemont L: Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 10(6), 961-969 (2009).
7. Cooper GM, Johnson JA, Langaee TY et al.: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027 (2008).
8. Borgiani P, Ciccacci C, Forte V et al.: CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10, 261-266 (2009).
9. The SEARCH Collaborative Group: SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med. 359, 789-799 (2008).
10. Martin ER, Lai EH, Gilbert JR et al.: SN Ping away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am. J. Hum. Genet. 67, 383-394 (2000).
11. Gomez A, Ingelman-Sundberg M: Epigenetic and microRNA dependent control of cytochrome P450 expression: a gap between DNA and protein. Pharmacogenomics (2009) 10.2217/PGS.09.56 (In press).
12. Johnson AD, Zhang Y, Papp AC et al.: Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet. Genomics 18, 781-791 (2008).
13. Jeannesson E, Siest G, Zaiou M, Berrahmoune H, Masson C, Visvikis-Siest S: Genetic profiling of human cell lines used as in vitro model to study cardiovascular physiopathology and pharmacotoxicology. Cell. Biol. Toxicol. (2009). (Epub ahead of print).
14. Arrell DK, Niederlander NJ, Perez-Terzic C, Chung S, Behfar A, Terzic A: Pharmacoproteomics: advancing the efficacy and safety of regenerative therapeutics. Clin. Pharmacol. Ther. 82, 316-319 (2007).
15. Shiota M, Kusakabe H, Hikita Y, Nakao T, Izumi Y, Iwao H: Pharmacogenomics of cardiovascular pharmacology: molecular network analysis in pleiotropic effects of statin - an experimental elucidation of the pharmacologic action from protein-protein interaction analysis. J. Pharmacol. Sci. 107, 15-19 (2008).
16. Arvanitidis K, Ragia G, Tavridou A, Manolopoulos VG: The prevalence of the novel CYP2C19*17 allele variant in the Greek population. Clin. Chem. Lab. Med. 46, A137 (2008) (Abstract).
17. Kim KA, Park PW, Park JY: Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur. J. Clin. Pharmacol. 64, 589-597 (2008).
18. Peñas-LLedó EM, Dorado P, Pacheco R, González I, LLerena A: Relation between CYP2D6 genotype personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics (2009). 10.2217/PGS.09.75 (In press).
19. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116, 496-526 (2007).
20. Kirchheiner J: Sex-specific differences in side effects of psychotropic drugs - genes or gender? Pharmacogenomics (2009) (In press).
21. Frueh FW, Amur S, Mummanneni P et al.: Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 28, 992-998 (2008).
22. Frueh FW: Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. Pharmacogenomics (2009) 10.2217/PGS.09.62 (In press).
23. Lacana E, Amur S, Mummanneni P, Zhao H, Frueh FW: The emerging role of pharmacogenomics in biologics. Clin. Pharmacol. Ther. 82, 466-471 (2007).
24. Owen RP, Klein TE, Altman RB: The education potential of the pharmacogenetics and pharmacogenomics knowledge base (PharmGKB). Clin. Pharmacol. Ther. 82, 472-475 (2007).
25. Tchele A: The Industry Pharmacogenomics Working Group: current activities. Clin. Chem. Lab. Med. 46, A120 (2008).
26. Crowley JJ, Sullivan PF, McLeod HL: Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics 10, 161-163 (2009).
27. Siest G, Jeannesson E, Marteau JB et al.: Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. Drug. Metab. Dispos. 36, 182-189 (2008).
28. Siest G, Marteau JB, Maumus S et al.: Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers. Eur. J. Pharmacol. 527, 1-22 (2005).